HZNP Horizon Pharma plc

12.02
+0.29  (2%)
Previous Close 11.73
Open 11.80
Price To book 1.58
Market Cap 1.96B
Shares 162,709,000
Volume 3,193,292
Short Ratio 2.01
Av. Daily Volume 4,464,890

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 8, 2016 - primary endpoint not met.
ACTIMMUNE
Friedreich's Ataxia (FA)

Latest News

  1. 3 Cheap Healthcare Stocks You Can Buy Right Now
  2. Horizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin nebuliser solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S.p.A.
  3. Horizon Pharma plc Partners with Global Genes® to Unite the Rare Disease Community at the Biotechnology Innovation Organization (BIO) International Convention
  4. Horizon Pharma Gets Health Canada Approval for Procysbi
  5. Horizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine Delayed-Release Capsules) for the Treatment of Nephropathic Cystinosis
  6. Valeant: Stop Looking in the Rearview Mirror!
  7. Horizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled Gout
  8. Epidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993
  9. Horizon Pharma (HZNP) Up 11.3% Since Earnings Report: Can It Continue?
  10. 3 Value Stocks You Probably Haven't Considered
  11. Falling Earnings Estimates Signal Weakness Ahead for Horizon Pharma (HZNP)
  12. ETFs with exposure to Horizon Pharma Plc : May 26, 2017
  13. 5 Stocks Setting Up for Big Breakouts
  14. Horizon Pharma plc to Participate in Upcoming Conferences
  15. Horizon Pharma plc Named One of the Best Workplaces in Chicago by Fortune
  16. Horizon (HZNP) Sells European Rights for Procysbi & Quinsair
  17. Horizon Pharma plc Announces Agreement to Sell European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S.p.A.
  18. Julian Robertson's Tiger Mgmt Sold Apple and Google, Bought Adobe in Q1
  19. Nuvo Pharmaceuticals™ Inc. Announces Topline Results from European Ankle Sprain Study with Pennsaid® 2%
  20. Nuvo Pharmaceuticals™ Announces District Court Decision to Uphold U.S. Pennsaid® 2% Patent